Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial

The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced... PURPOSENephrotoxicity is a major dose-limiting toxicity among patients with cancer who were treated with cisplatin. Although no standard approach is available to prevent cisplatin-induced nephrotoxicity, administering intravenous isotonic saline is recommended. Additionally, mannitol combined with hydration has been evaluated, but none of them have been established. Our study aimed to determine the efficacy of mannitol combined hydration to prevent cisplatin-induced nephrotoxicity.PATIENTS AND METHODSThis study was a phase II, randomized, placebo-controlled design. All patients with solid cancers who were treated with cisplatin (n = 48) were randomly assigned to receive either placebo (n = 25) or 20 g of mannitol (n = 23) after completing 2 L of prehydration and receiving cisplatin. Serum creatinine, blood urea nitrogen, electrolyte, and glomerular filtration rate (GFR) were measured at baseline and days 2 and 7. Moreover, GFR was calculated based on the 24-hour urine creatinine clearance rate to assess renal function at baseline and 48 hours after receiving cisplatin. Severity of nausea and vomiting was evaluated using Common Terminology Criteria for Adverse Events.RESULTSNo difference was found regarding baseline characteristics between the two groups. Seven of 23 patients (37.4%) in the mannitol group and 10 of 25 patients (40%) in the placebo group increased serum creatinine level ≥ 0.3 mg/dL at 48 hours after intervention (P value = .48). Patients receiving mannitol exhibited significantly lower incidence of 24-hour urine GFR below 60 mL/min/1.73 m than those in the placebo group (13.6% v 48.0% in the placebo group; P value = .012). Univariate analysis showed the greatest benefit for administering mannitol among patients receiving cisplatin > 80 mg/m2, or patients receiving concomitant radiation.CONCLUSIONMannitol combined with hydration significantly prevented cisplatin-induced nephrotoxicity. Additionally, mannitol should be particularly considered among patients with cancer, treated with cisplatin > 80 mg/m2, or patients receiving concomitant radiation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JCO: Global Oncology Wolters Kluwer Health

The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial

Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/the-effect-of-intravenous-mannitol-combined-with-normal-saline-in-p4SLvXYDLQ

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
© 2022 by American Society of Clinical Oncology
eISSN
2687-8941
DOI
10.1200/go.21.00275
Publisher site
See Article on Publisher Site

Abstract

PURPOSENephrotoxicity is a major dose-limiting toxicity among patients with cancer who were treated with cisplatin. Although no standard approach is available to prevent cisplatin-induced nephrotoxicity, administering intravenous isotonic saline is recommended. Additionally, mannitol combined with hydration has been evaluated, but none of them have been established. Our study aimed to determine the efficacy of mannitol combined hydration to prevent cisplatin-induced nephrotoxicity.PATIENTS AND METHODSThis study was a phase II, randomized, placebo-controlled design. All patients with solid cancers who were treated with cisplatin (n = 48) were randomly assigned to receive either placebo (n = 25) or 20 g of mannitol (n = 23) after completing 2 L of prehydration and receiving cisplatin. Serum creatinine, blood urea nitrogen, electrolyte, and glomerular filtration rate (GFR) were measured at baseline and days 2 and 7. Moreover, GFR was calculated based on the 24-hour urine creatinine clearance rate to assess renal function at baseline and 48 hours after receiving cisplatin. Severity of nausea and vomiting was evaluated using Common Terminology Criteria for Adverse Events.RESULTSNo difference was found regarding baseline characteristics between the two groups. Seven of 23 patients (37.4%) in the mannitol group and 10 of 25 patients (40%) in the placebo group increased serum creatinine level ≥ 0.3 mg/dL at 48 hours after intervention (P value = .48). Patients receiving mannitol exhibited significantly lower incidence of 24-hour urine GFR below 60 mL/min/1.73 m than those in the placebo group (13.6% v 48.0% in the placebo group; P value = .012). Univariate analysis showed the greatest benefit for administering mannitol among patients receiving cisplatin > 80 mg/m2, or patients receiving concomitant radiation.CONCLUSIONMannitol combined with hydration significantly prevented cisplatin-induced nephrotoxicity. Additionally, mannitol should be particularly considered among patients with cancer, treated with cisplatin > 80 mg/m2, or patients receiving concomitant radiation.

Journal

JCO: Global Oncology – Wolters Kluwer Health

Published: Apr 18, 2022

References

  • Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A southwest oncology group study
    Al-Sarraf, M; Fletcher, W; Oishi, N
  • Platinum nephrotoxicity
    Madias, NE; Harrington, JT
  • Cisplatin nephrotoxicity: A review of the literature
    Manohar, S; Leung, N
  • Rates of renal toxicity in cancer patients receiving cisplatin with and without mannitol
    Morgan, KP; Snavely, AC; Wind, LS
  • A systematic review of strategies to prevent cisplatin-induced nephrotoxicity
    Crona, DJ; Faso, A; Nishijima, TF
  • Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy
    McKibbin, T; Cheng, LL; Kim, S
  • Improvement of cis-dichlorodiammineplatinum (NSC 119875): Therapeutic index in an animal model
    Cvitkovic, E; Spaulding, J; Bethune, V
  • Long-term renal outcomes after cisplatin treatment
    Latcha, S; Jaimes, EA; Patil, S
  • High-dose cisplatin therapy using mannitol versus furosemide diuresis: Comparative pharmacokinetics and toxicity
    Ostrow, S; Egorin, MJ; Hahn, D
  • Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: A randomized trial
    Santoso, JT; Lucci, JA; Coleman, RL
  • Effect of low‐dose prophylactic dopamine on high‐dose cisplatin‐induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: A randomized, placebo‐controlled, double‐blind trial
    Somlo, G; Doroshow, JH; Lev‐Ran, A
  • Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin
    Yamamoto, Y; Watanabe, K; Tsukiyama, I
  • The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
    Vimolchalao, V; Sakdejayont, S; Wongchanapai, P